This inventor holds 23 USPTO granted patents and 2 published patent applications, primarily in Peptide Conjugates. Top assignees: Marker Gene Technologies, Inc, Molecular Probes, Inc., Biolog, Inc.. Active years: 1993-2020.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
12 out of 12 
6 out of 83 
2 out of 24 Years Active: 1993-2020
Areas of Expertise:
Title: Innovations in Targeted Therapeutics: The Contributions of John Joseph Naleway
Introduction
John Joseph Naleway, based in Eugene, OR, has made significant contributions to the field of therapeutics, specifically through his innovative patents. With a remarkable portfolio of 23 patents, his work primarily focuses on the development of targeted peptide conjugates for therapeutic applications.
Latest Patents
Naleway's latest inventions include "Targeted peptide conjugates" and "Intracellular organelle peptide targeted enzyme substrates." The targeted peptide conjugates invention offers methods for preparing therapeutic compounds aimed at specific subcellular target areas, like lysosomes and mitochondria. These compounds are designed to modify enzyme activity within targeted cellular organelles, paving the way for more effective disease treatment.
The invention concerning intracellular organelle peptide targeted enzyme substrates relates to substrates that enable visualization of intracellular organelles through enzyme activity. These compounds are particularly noteworthy because they produce high fluorescence signals under lower pH conditions typical of certain organelles, allowing for monitoring of enzyme activity within cells at minimal concentrations.
Career Highlights
Throughout his career, Naleway has worked with notable companies, including Marker Gene Technologies, Inc. and Molecular Probes, Inc., where he honed his skills in peptide technology and therapeutic development. His innovative approaches have positioned him as a prominent figure in the scientific community.
Collaborations
Naleway's collaborative work has been enriched by partnerships with esteemed colleagues like Richard P. Haugland and Daniel J. Coleman. Together, they have explored the intricacies of enzyme activity and targeted therapies, contributing valuable insights to the field.
Conclusion
John Joseph Naleway's dedication to innovation in therapeutic development through targeted peptides highlights the importance of specific organelle targeting in the treatment of diseases. His contributions have opened new avenues in biological research and pharmaceutical applications, showing the potential of targeted therapies in improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile